Rosuvastatin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metabolic Syndrome
Conditions
Metabolic Syndrome, Dyslipidemia
Trial Timeline
Apr 1, 2004 → May 1, 2006
NCT ID
NCT00240305About Rosuvastatin
Rosuvastatin is a phase 3 stage product being developed by AstraZeneca for Metabolic Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00240305. Target conditions include Metabolic Syndrome, Dyslipidemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00160745 | Phase 2 | Completed |
| NCT04846231 | Phase 2 | Completed |
| NCT02561845 | Pre-clinical | Withdrawn |
| NCT02484027 | Approved | UNKNOWN |
| NCT02077257 | Approved | UNKNOWN |
| NCT01837823 | Phase 2 | Completed |
| NCT01490398 | Approved | Completed |
| NCT01364220 | Phase 3 | Terminated |
| NCT00815659 | Approved | Completed |
| NCT00747149 | Approved | Completed |
| NCT00473655 | Approved | Completed |
| NCT00335699 | Approved | Completed |
| NCT00184951 | Phase 2 | Completed |
| NCT00240305 | Phase 3 | Completed |
| NCT00176332 | Phase 2 | Completed |
| NCT00228514 | Phase 3 | Completed |
| NCT00240266 | Phase 3 | Completed |
| NCT00241488 | Phase 3 | Completed |
| NCT00660764 | Pre-clinical | Completed |
| NCT00239681 | Phase 3 | Terminated |
Competing Products
20 competing products in Metabolic Syndrome